Brickley Elizabeth B, Spottiswoode Natasha, Kabyemela Edward, Morrison Robert, Kurtis Jonathan D, Wood Angela M, Drakesmith Hal, Fried Michal, Duffy Patrick E
Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland. Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom. Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland. Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom. Department of Microbiology and Immunology, Columbia University College of Physicians and Surgeons, New York, New York.
Am J Trop Med Hyg. 2016 Oct 5;95(4):817-826. doi: 10.4269/ajtmh.16-0218. Epub 2016 Jun 27.
Hepcidin, the master regulator of bioavailable iron, is a key mediator of anemia and also plays a central role in host defense against infection. We hypothesized that measuring hepcidin levels in cord blood could provide an early indication of interindividual differences in iron regulation with quantifiable implications for anemia, malaria, and mortality-related risk. Hepcidin concentrations were measured in cord plasma from a birth cohort (N = 710), which was followed for up to 4 years in a region of perennial malaria transmission in Muheza, Tanzania (2002-2006). At the time of delivery, cord hepcidin levels were correlated with inflammatory mediators, iron markers, and maternal health conditions. Hepcidin levels were 30% (95% confidence interval [CI]: 12%, 44%) lower in children born to anemic mothers and 48% (95% CI: 11%, 97%) higher in placental malaria-exposed children. Relative to children in the lowest third, children in the highest third of cord hepcidin had on average 2.5 g/L (95% CI: 0.1, 4.8) lower hemoglobin levels over the duration of follow-up, increased risk of anemia and severe anemia (adjusted hazard ratio [HR] [95% CI]: 1.18 [1.03, 1.36] and 1.34 [1.08, 1.66], respectively), and decreased risk of malaria and all-cause mortality (adjusted HR [95% CI]: 0.78 [0.67, 0.91] and 0.34 [0.14, 0.84], respectively). Although longitudinal measurements of hepcidin and iron stores are required to strengthen causal inference, these results suggest that hepcidin may have utility as a biomarker indicating children's susceptibility to anemia and infection in early life.
铁调素是生物可利用铁的主要调节因子,是贫血的关键介质,在宿主抗感染防御中也起着核心作用。我们推测,检测脐带血中铁调素水平可以早期提示个体间铁调节的差异,对贫血、疟疾和死亡相关风险具有可量化的影响。在坦桑尼亚穆赫扎常年疟疾传播地区(2002 - 2006年),对一个出生队列(N = 710)的脐带血浆中铁调素浓度进行了测量,并对其进行了长达4年的随访。分娩时,脐带铁调素水平与炎症介质、铁标志物和母亲健康状况相关。贫血母亲所生儿童的铁调素水平低30%(95%置信区间[CI]:12%,44%),胎盘疟疾暴露儿童的铁调素水平高48%(95%CI:11%,97%)。在随访期间,相对于铁调素水平最低三分位的儿童,最高三分位的儿童平均血红蛋白水平低2.5 g/L(95%CI:0.1,4.8),贫血和重度贫血风险增加(校正风险比[HR][95%CI]:分别为1.18[1.03,1.36]和1.34[1.08,1.66]),疟疾和全因死亡率风险降低(校正HR[95%CI]:分别为0.78[0.67,0.91]和0.34[0.1 , 0.84])。尽管需要对铁调素和铁储备进行纵向测量以加强因果推断,但这些结果表明,铁调素可能作为一种生物标志物,用于指示儿童在生命早期对贫血和感染的易感性。